<DOC>
	<DOCNO>NCT01955720</DOCNO>
	<brief_summary>To investigate safety , tolerability , PK PD BI 655075 establish BI 655075 dose ( ) effective reverse prolongation blood coagulation time dabigatran</brief_summary>
	<brief_title>Safety , Tolerability , PK PD BI 655075 Establishment BI 655075 Dose ( ) Effective Reverse Prolongation Blood Coagulation Time Dabigatran</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : Healthy midage male female volunteer , age =45 =64 year , BMI range : =18.5 =29.9 kg/m2 Healthy elderly male female volunteer , age =65 =80 year , BMI range : =18.5 = 32 kg/m2 Male female volunteer mild renal impairment ( CLcrd 6090 ( mL/min ) ) relatively good health , age =45 =80 year , BMI range : =18.5 =32 kg/m2 Moderate renal impaired ( CLcrd =30 &lt; 60 mL/min accord Cockcroft &amp; Gault formula relatively good health , age =45 =80 year , BMI range : =18.5 =32 kg/m2 Exclusion criterion : Any find medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease ( mild renal impairment respective group ) A significant disease define disease opinion investigator put volunteer risk participation study may influence result study may influence volunteerÂ¿s ability participate study stable condition Diabetic , hypercholesterolemia hypertensive subject enter trial disease significant accord criterion Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackout . Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients )</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>